Tew - PDFSEARCH.IO - Document Search Engine

Tew
Results: 140

#	Item
31	Shionogi & Co., Ltd. Shionogi & Co., Ltd. to Acquire the Shares and to Conduct a General Offer for China-based C&O Pharmaceutical Technology (Holdings) Limited Osaka, Japan, August 18, Shionogi & Co., Ltd. (Head Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:17 Government procurement in the United States Economy of Asia Asia Shionogi Economy of Singapore Singapore Exchange
32	Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:22 Medicine HIV/AIDS Cyclopropanes Integrase inhibitors Amides Lamivudine Zidovudine Antiretroviral drug GlaxoSmithKline Chemistry Organic chemistry Organofluorides
33	Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1  Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:21 Organic chemistry Health HIV/AIDS Amides Oxadiazoles Raltegravir Lamivudine GlaxoSmithKline Dolutegravir Organofluorides Chemistry Integrase inhibitors
34	Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1 Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2015-01-27 15:09:34 Shionogi Menopause Dyspareunia Estrogen Vaginal lubrication Human reproduction Endocrine system Reproductive system
35	Shionogi & Co., Ltd. Shionogi Announces the Conducting of Drug Discovery Competition FINDS2010 -Drug seeds fostering type- Osaka, June 1, 2010 – Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; he Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:17 Pharmacy Drug discovery Pharmaceutical sciences Pharmacology Shionogi
36	Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:11 Sulfonamides Medicine Carbamates Darunavir HIV/AIDS Antiretroviral drug ViiV Healthcare Zidovudine Integrase inhibitor Protease inhibitors Chemistry Biology
37	April 16, 2010 Shionogi & Co., Ltd. Eli Lilly Japan K.K. Launch of an Antidepressant Drug, “Cymbalta® Capsules 20mg and 30mg” Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “ Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:18 Amines Phenols Serotonin-norepinephrine reuptake inhibitors Duloxetine Thiophenes Shionogi Serotonin–norepinephrine reuptake inhibitor Antidepressant Major depressive disorder Chemistry Organic chemistry Eli Lilly and Company
38	February 15, 2010 Shionogi & Co., Ltd. Shionogi Files an Additional Application for Pediatric Use of “RAPIACTA®’’ a Novel Anti-viral Drug for Influenza Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:21 Chemistry Acetamides Vaccines Guanidines Animal virology Peramivir FluMist Neuraminidase Shionogi Neuraminidase inhibitors Biology Influenza
39	Antitrichomonal Agent, Flagyl® Approval for Additional Indication of Bacterial Vaginosis Osaka, Japan, March 21, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shio Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:19 Metronidazole Pfizer Sanofi Shionogi Pharmacology Trichomoniasis Bacterial vaginosis Off-label use Medicine Antiprotozoal agents Health
40	Synthetic Antibacterial Agent, Baktar® Approval for Additional Indication of Prophylaxis and Treatment for Pneumocystis Pneumonia Osaka, Japan, August 10, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:18 Antibiotics Pyrimidines Pneumocystis pneumonia Pneumonia Shionogi Pharmacology Trimethoprim Off-label use Sulfamethoxazole Aromatic amines Chemistry Organic chemistry

UPDATE